Checkpoint Inhibitor-induced Liver Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

160 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-10-13

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this multi-center prospective observational study, the investigators plan to identify the incidence and risk factors for checkpoint inhibitor-induced liver injury and characterize biochemical, genetic, immunological, and histological features associated with it.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

NCT04772612

Hepatic Impairment

COMPLETED PHASE1

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

NCT00418626

Healthy

COMPLETED PHASE1

A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment

NCT02387814

Hepatic Insufficiency

COMPLETED PHASE1

Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function

NCT02521376

Oncology

COMPLETED PHASE1

A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

NCT06888115

Primary Biliary Cholangitis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Checkpoint inhibitor-induced liver injury (ChILI) is a new incompletely understood category of hepatotoxicity which is distinct from other types of drug-induced liver injury (DILI) such as direct or idiosyncratic DILI. The data regarding the incidence and risk factors is lacking. Therefore, 'in-depth phenotyping' together with data from the control group exposed to checkpoint inhibitors (CPI) is necessary to develop refined algorithms incorporating CPI-related factors, host genetic and environmental risk factors that would enable pre-empting ChILI.

The aim of the study is to enroll two deeply phenotyped cohorts (patients who developed ChILI and patients who are starting checkpoint inhibitors) and obtain biological samples at multiple time points.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immune-Mediated Hepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ChILI

Patients who are already on CPI therapy and have developed liver injury

Obtaining biological samples

Intervention Type DIAGNOSTIC_TEST

Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated

Control

Patients with cancer who are starting on checkpoint inhibitors

Obtaining biological samples

Intervention Type DIAGNOSTIC_TEST

Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Obtaining biological samples

Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Both patient groups and control group:

• Able to give written informed consent OR Potential participants who have developed encephalopathy related to ChILI as a response to checkpoint inhibitor therapy, who lack the capacity to give written informed consent and have a consultee (personal or nominated) - for ChILI patient group only

ChILI group:

Patients who developed checkpoint inhibitor-induced liver injury and meet the following criteria:

1. Meets one of the following analytical thresholds at enrolment (visit 1)

* Alanine transaminase (ALT) exceeding 5 times the upper limit of normal (ULN) OR
* ALT exceeding 3 times ULN plus bilirubin exceeding 2 times ULN OR
* Alkaline phosphatase (ALP) exceeding 2 times ULN with accompanying elevations of gamma-glutamyl transferase in the absence of known bone metastases driving the rise in ALP level
2. Absence of other known causes of liver injury after detailed investigations

Patients who developed ChILI but did not meet the above criteria at enrolment or who were found to have a different cause for their liver injury after further investigations will be excluded from the analysis

Control group:

Consecutive patients with cancer who have a clinical indication to start checkpoint inhibitors. A small proportion of patients will develop ChILI following their checkpoint inhibitor treatment and will be classified as cases.

Exclusion Criteria

* Patients who are treated with cytotoxic chemotherapy concurrently with checkpoint inhibitors.
* On the judgment of chief investigator that the person has certain alternative explanations to the acute event (rather than ChILI).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No